Diabetes Drug Exenatide Reduces Inflammation in Rheumatoid Arthritis Joint Cells | Research

The takeaway

The GLP-1 agonist exenatide reduced multiple markers of inflammation and oxidative stress in human rheumatoid arthritis synovial cells, suggesting potential as a repurposed treatment for RA.

GLP-1R on joint cells
The study confirms GLP-1 receptors are present on RA synoviocytes, opening a new therapeutic target for arthritis

What the researchers found

Exenatide, acting through the GLP-1 receptor on human fibroblast-like synoviocytes (FLS), demonstrated multiple anti-inflammatory and protective effects in RA joint cells stimulated with TNF-α. Specifically, exenatide:

- Increased mitochondrial membrane potential, reversing TNF-α-induced mitochondrial dysfunction

- Reduced reactive oxygen species (ROS) production and NADPH oxidase 4 expression

- Decreased expression of tissue-degrading enzymes MMP-3 and MMP-13

- Lowered release of proinflammatory cytokines IL-1β, IL-6, MCP-1, and HMGB1

- Inhibited the p38/IκBα/NF-κB signaling pathway, a key inflammatory cascade

Why it matters

Rheumatoid arthritis affects millions worldwide and current treatments have significant side effects or lose effectiveness over time. Finding new anti-inflammatory uses for existing, well-characterized drugs like exenatide could accelerate the path to new RA therapies. This study also reveals that GLP-1 receptors exist on joint cells — a finding that opens a new avenue for understanding how metabolic and inflammatory pathways intersect.

How the study worked

The researchers used primary human fibroblast-like synoviocytes (FLS) from rheumatoid arthritis patients grown in cell culture. They stimulated these cells with TNF-α to mimic the inflammatory environment of an RA joint, then treated them with exenatide. They measured changes in mitochondrial function, oxidative stress markers, inflammatory cytokines, matrix metalloproteinases, and signaling pathway activation.

What this study cannot tell us

This was an in vitro study using cells in a dish, not a clinical trial. The inflammatory conditions were artificially induced with TNF-α, which may not fully replicate the complex inflammatory environment of an RA joint. Specific concentrations of exenatide used and whether they are achievable in joint tissue in vivo were not discussed in the abstract. No animal model or human clinical data was presented.

How to read the evidence

This is an in vitro cell culture study using human RA synoviocytes. While the mechanistic data is detailed, no animal or human clinical data is presented, placing this at an early preclinical evidence level.

When this study was published

Published in 2019, this study predates the recent surge of interest in GLP-1 agonists' anti-inflammatory properties. Its findings have become more relevant as the field explores broader applications of this drug class.

The bigger picture

This study is part of a growing body of research showing that GLP-1 receptor agonists have anti-inflammatory effects far beyond their metabolic role. As semaglutide and tirzepatide attract attention for cardiovascular and kidney benefits, studies like this extend the potential of the GLP-1 peptide class into autoimmune disease. Drug repurposing from diabetes to RA could significantly shorten development timelines since exenatide's safety profile is already well-established.

Questions still open

Can exenatide reach therapeutic concentrations in joint tissue when administered systemically for diabetes?
Would other GLP-1 receptor agonists like semaglutide or liraglutide show similar anti-inflammatory effects on RA synoviocytes?
Could the anti-inflammatory mechanism observed here explain some of the broader cardiovascular benefits seen with GLP-1 agonists in diabetes patients?

Common questions

What is exenatide and why was it tested for arthritis?

Exenatide is a peptide drug that mimics the gut hormone GLP-1 and is approved for treating type 2 diabetes. Researchers tested it for arthritis because GLP-1 receptor agonists have shown anti-inflammatory properties in other contexts, and they discovered that joint lining cells in RA patients actually have GLP-1 receptors — meaning they can respond to this drug.

Does this mean people with rheumatoid arthritis should take exenatide?

No — this was a laboratory study on cells, not a clinical trial. While the results are promising, much more research including animal studies and human trials would be needed before exenatide could be recommended for RA. However, it does suggest that patients with both diabetes and RA who take GLP-1 agonists might experience some incidental anti-inflammatory benefit.

Read the original research

Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes.

IUBMB life, 71(7), 969-977

View on PubMed ↗Publisher’s paper ↗

Citation

Tao, Yunxia; Ge, Gaoran; Wang, Qing; Wang, Wei; Zhang, Wenhao; Bai, Jiaxiang; Lin, Jiayi; Shen, Jining; Guo, Xiaobin; Xu, Yaozeng; Geng, Dechun. (2019). Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes.. IUBMB life, 71(7), 969-977. https://doi.org/10.1002/iub.2031